#BEGIN_DRUGCARD DB03013

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
50670

# Chemical_Formula:
C16H28N2O11

# Chemical_IUPAC_Name:
N-[(2R,3R,4R,5R,6R)-5-{[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Di(N-Acetyl-D-Glucosamine)

# HET_ID:
CBS

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C16H28N2O11/c1-5(21)17-9-13(25)14(8(4-20)27-15(9)26)29-16-10(18-6(2)22)12(24)11(23)7(3-19)28-16/h7-16,19-20,23-26H,3-4H2,1-2H3,(H,17,21)(H,18,22)/t7-,8-,9-,10-,11+,12-,13-,14+,15-,16+/m1/s1

# InChI_Key:
InChIKey=CDOJPCSDOXYJJF-OSJSAICRSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3013

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
424.4003

# Molecular_Weight_Mono:
424.169309748

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1C7T

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.6

# Predicted_LogS:
-0.58

# Predicted_Water_Solubility:
1.11e+02 g/l

# Primary_Accession_No:
DB03013

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936555

# PubChem_Substance_ID:
46505382

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00851

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2NC(C)=O)[C@@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:49 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Periplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L43594

# Drug_Target_1_GenBank_ID_Protein:
1369888

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
chb

# Drug_Target_1_Gene_Sequence:
>2658 bp
ATGAACGCATTCAAACTGAGCGCGCTTGCCCGCTTGACGGCAACGATGGGATTCCTGGGC
GGTATGGGGAGCGCCATGGCCGATCAACAGCTGGTGGATCAACTGAGCCAGCTGAAGCTG
AACGTGAAAATGCTGGATAACCGCGCCGGCGAAAACGGCGTGGATTGCGCGGCGCTGGGC
GCTGACTGGGCTTCTTGCAACCGGGTGTTGTTCACCCTCAGCAACGACGGCCAGGCGATC
GACGGCAAAGACTGGGTCATCTATTTCCACAGCCCGCGGCAGACCTTGCGGGTGGACAAC
GACCAGTTCAAGATCGCGCATCTGACCGGCGATCTGTACAAGCTGGAGCCGACCGCCAAA
TTCAGCGGTTTCCCGGCCGGTAAGGCGGTGGAAATCCCGGTGGTCGCCGAATACTGGCAG
CTGTTCAGAAACGACTTCCTGCCGCGTTGGTATGCCACCTCCGGCGACGCCAAGCCGAAA
ATGCTGGCGAATACCGACACCGAAAACCTGGATCAGTTTGTGGCGCCGTTCACCGGCGAC
CAGTGGAAGCGCACCAAGGACGACAAAAACATTCTGATGACGCCGGCTTCGCGCTTTGTC
AGCAATGCCGATCTGCAGACGCTGCCCGCCGGCGCGCTGCGCGGCAAGATCGTGCCGACG
CCGATGCAGGTGAAGGTCCACGCACAGGACGCCGACCTGCGCAAAGGGGTGGCGCTGGAT
CTGAGCACGCTGGTCAAGCCGGCGGCGGACGTCGTCAGTCAGCGTTTCGCGCTGCTGGGC
GTGCCGGTTCAGACCAACGGTTACCCGATCAAGACCGATATCCAGCCGGGCAAGTTTAAA
GGCGCGATGGCGGTATCGGGCGCCTATGAGCTGAAAATCGGCAAGAAAGAGGCGCAAGTG
ATCGGCTTCGATCAGGCCGGGGTGTTCTACGGGCTGCAGTCGATCCTGTCGTTAGTGCCG
AGCGACGGCAGCGGCAAGATCGCCACGCTGGACGCCAGCGATGCGCCGCGCTTCCCGTAT
CGCGGCATTTTCCTCGACGTGGCGCGCAACTTCCATAAGAAGGACGCGGTGCTGCGTCTG
CTGGATCAGATGGCGGCTTACAAGCTCAATAAATTCCACTTCCACCTGAGCGATGACGAA
GGCTGGCGCATCGAGATCCCCGGCTTGCCTGAGTTGACGGAAGTCGGCGGCCAGCGCTGC
CACGATCTGAGCGAAACCACCTGCCTGCTGCCGCAGTACGGCCAGGGGCCGGACGTCTAC
GGCGGCTTCTTCAGCCGTCAGGACTACATCGACATCATCAAATACGCCCAGGCGCGCCAG
ATTGAGGTGATCCCGGAGATCGACATGCCGGCGCACGCGCGCGCCGCGGTGGTTTCGATG
GAAGCGCGCTATAAAAAGCTGCATGCCGCTGGCAAAGAGCAGGAGGCCAACGAATTCCGT
CTGGTGGATCCGACCGATACCTCCAACACCACCTCCGTGCAGTTCTTTAACCGCCAGAGC
TACCTGAACCCGTGCCTGGATTCCTCCCAGCGCTTTGTCGACAAGGTGATCGGCGAGATT
GCCCAGATGCATAAAGAAGCCGGGCAGCCGATCAAGACCTGGCACTTTGGCGGCGATGAG
GCGAAAAACATCCGCCTGGGCGCCGGCTATACCGACAAGGCGAAACCGGAACCGGGTAAA
GGCATCATTGACCAGAGTAATGAAGACAAGCCGTGGGCCAAGTCGCAGGTGTGCCAGACG
ATGATCAAAGAGGGCAAAGTAGCCGACATGGAGCACCTGCCGAGCTACTTCGGCCAGGAG
GTCAGCAAGCTGGTGAAGGCGCACGGCATCGATAGAATGCAGGCCTGGCAAGACGGCCTG
AAAGACGCCGAAAGTTCGAAGGCGTTCGCCACCTCGCGCGTGGGCGTCAACTTCTGGGAC
ACCCTGTATTGGGGCGGTTTCGACAGCGTTAACGACTGGGCCAATAAAGGGTATGAAGTG
GTGGTCTCCAACCCGGACTACGTCTACATGGACTTCCCTTACGAGGTGAATCCGGACGAG
CGCGGTTACTACTGGGGCACCCGCTTCAGCGACGAGCGCAAGGTGTTCAGCTTCGCGCCG
GACAACATGCCGCAGAACGCGGAAACCTCGGTCGACCGCGACGGCAACCACTTCAACGCC
AAAAGCGACAAGCCGTGGCCGGGCGCCTACGGTCTGTCCGCTCAGCTGTGGAGCGAAACC
CAGCGCACCGATCCGCAGATGGAATACATGATCTTCCCGCGCGCGCTTTCGGTGGCGGAA
CGGTCCTGGCACCGCGCCGGTTGGGAGCAGGACTATCGCGCCGGCCGCGAATACAAAGGC
GGGGAAACCCACTTTGTCGATACCCAGGCGCTGGAGAAAGACTGGCTGCGCTTCGCCAAT
ATCCTGGGCCAACGTGAACTGGCCAAGCTGGACAAAGGCGGCGTCGCTTATCGTCTGCCG
GTGCCGGGTGCCCGCGTGGCGGCTGGCAAGCTGGAAGCGAATATCGCGCTGCCGGGATTG
GGCATCGAGTATTCCACCGACGGCGGCAAGCAGTGGCAGCGCTATGACGCCAAGGCCAAG
CCGGCGGTCTCCGGTGAAGTGCAGGTGCGTTCGGTCAGCCCGGACGGTAAACGCTACAGC
CGCGCCGAGAAGGTCTAG

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
8621090	Tews I, Vincentelli R, Vorgias CE: N-Acetylglucosaminidase (chitobiase) from Serratia marcescens: gene sequence, and protein production and purification in Escherichia coli. Gene. 1996 Apr 17;170(1):63-7.
8673609	Tews I, Perrakis A, Oppenheim A, Dauter Z, Wilson KS, Vorgias CE: Bacterial chitobiase structure provides insight into catalytic mechanism and the basis of Tay-Sachs disease. Nat Struct Biol. 1996 Jul;3(7):638-48.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2916

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
98549

# Drug_Target_1_Name:
Chitobiase

# Drug_Target_1_Number_of_Residues:
885

# Drug_Target_1_PDB_ID:
1QBB

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00728	Glyco_hydro_20
PF02838	Glyco_hydro_20b
PF03173	CHB_HEX
PF03174	CHB_HEX_C

# Drug_Target_1_Protein_Sequence:
>Chitobiase precursor
MNAFKLSALARLTATMGFLGGMGSAMADQQLVDQLSQLKLNVKMLDNRAGENGVDCAALG
ADWASCNRVLFTLSNDGQAIDGKDWVIYFHSPRQTLRVDNDQFKIAHLTGDLYKLEPTAK
FSGFPAGKAVEIPVVAEYWQLFRNDFLPRWYATSGDAKPKMLANTDTENLDQFVAPFTGD
QWKRTKDDKNILMTPASRFVSNADLQTLPAGALRGKIVPTPMQVKVHAQDADLRKGVALD
LSTLVKPAADVVSQRFALLGVPVQTNGYPIKTDIQPGKFKGAMAVSGAYELKIGKKEAQV
IGFDQAGVFYGLQSILSLVPSDGSGKIATLDASDAPRFPYRGIFLDVARNFHKKDAVLRL
LDQMAAYKLNKFHFHLSDDEGWRIEIPGLPELTEVGGQRCHDLSETTCLLPQYGQGPDVY
GGFFSRQDYIDIIKYAQARQIEVIPEIDMPAHARAAVVSMEARYKKLHAAGKEQEANEFR
LVDPTDTSNTTSVQFFNRQSYLNPCLDSSQRFVDKVIGEIAQMHKEAGQPIKTWHFGGDE
AKNIRLGAGYTDKAKPEPGKGIIDQSNEDKPWAKSQVCQTMIKEGKVADMEHLPSYFGQE
VSKLVKAHGIDRMQAWQDGLKDAESSKAFATSRVGVNFWDTLYWGGFDSVNDWANKGYEV
VVSNPDYVYMDFPYEVNPDERGYYWGTRFSDERKVFSFAPDNMPQNAETSVDRDGNHFNA
KSDKPWPGAYGLSAQLWSETQRTDPQMEYMIFPRALSVAERSWHRAGWEQDYRAGREYKG
GETHFVDTQALEKDWLRFANILGQRELAKLDKGGVAYRLPVPGARVAAGKLEANIALPGL
GIEYSTDGGKQWQRYDAKAKPAVSGEVQVRSVSPDGKRYSRAEKV

# Drug_Target_1_Reaction:
Hydrolysis of terminal non-reducing N-acetyl-D-hexosamine residues in N-acetyl-beta-D-hexosaminides ALL_REAC (other) R00022 R03492 R04184 R04586 R05963(G) R06001(G) R06004(G) R06141(G) R07809(G) R07810(G)

# Drug_Target_1_Signals:
1-27

# Drug_Target_1_Specific_Function:
Digests the beta-1,4-glycosidic bonds in N- acetylglucosamine (GlcNAc) oligomers (mainly dimers)

# Drug_Target_1_SwissProt_ID:
Q54468

# Drug_Target_1_SwissProt_Name:
CHB_SERMA

# Drug_Target_1_Synonyms:
Beta-N-acetylhexosaminidase
Chitobiase precursor
EC 3.2.1.52
N-acetyl-beta-glucosaminidase

# Drug_Target_1_Theoretical_pI:
6.73

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
LYZ

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6252

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Lysozyme C

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P61626

# Drug_Target_2_SwissProt_Name:
LYSC_HUMAN

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

# Drug_Target_3_Cellular_Location:
Golgi stack
Golgi stack membrane
Isoform Long, isoform Short:Golgi apparatus
single-pass type II

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
B4GALT1

# Drug_Target_3_GenBank_ID_Gene:
X14085

# Drug_Target_3_GenBank_ID_Protein:
29424

# Drug_Target_3_GeneCard_ID:
B4GALT1

# Drug_Target_3_Gene_Name:
B4GALT1

# Drug_Target_3_Gene_Sequence:
>1203 bp
ATGAGGCTTCGGGAGCCGCTCCTGAGCGGCGCCGCGATGCCAGGCGCGTCCCTACAGCGG
GCCTGCCGCCTGCTCGTGGCCGTCTGCGCTCTGCACCTTGGCGTCACCCTCGTTTACTAC
CTGGCTGGCCGCGACCTGAGCCGCCTGCCCCAACTGGTCGGAGTCTCCACACCGCTGCAG
GGCGGCTCGAACAGTGCCGCCGCCATCGGGCAGTCCTCCGGGGAGCTCCGGACCGGAGGG
GCCCGGCCGCCGCCTCCTCTAGGCGCCTCCTCCCAGCCGCGCCCGGGTGGCGACTCCAGC
CCAGTCGTGGATTCTGGCCCTGGCCCCGCTAGCAACTTGACCTCGGTCCCAGTGCCCCAC
ACCACCGCACTGTCGCTGCCCGCCTGCCCTGAGGAGTCCCCGCTGCTTGTGGGCCCCATG
CTGATTGAGTTTAACATGCCTGTGGACCTGGAGCTCGTGGCAAAGCAGAACCCAAATGTG
AAGATGGGCGGCCGCTATGCCCCCAGGGACTGCGTCTCTCCTCACAAAGTGGCCATCATC
ATTCCATTCCGCAACCGGCAGGAGCACCTCAAGTACTGGCTATATTATTTGCACCCAGTC
CTGCAGCGCCAGCAGCTGGACTATGGCATCTATGGCATCTATGTTATCAACCAGGCGGGA
GACACTATATTCAATCGTGCTAAGCTCCTCAATGTTGGCTTTCAAGAAGCCTTGAAGGAC
TATGACTACACCTGCTTTGTGTTTAGTGACGTGGACCTCATCCCAATGAATGACCATAAT
GCGTACAGGTGTTTTTCACAGCCACGGCACATTTCCGTTGCAATGGATAAGTTTGGATTC
AGCCTACCTTATGTTCAGTATTTTGGAGGTGTCTCTGCTCTAAGTAAACAACAGTTTCTA
ACCATCAATGGATTTCCTAATAATTATTGGGGCTGGGGAGGAGAAGATGATGACATTTTT
AACAGATTAGTTTTTAGAGGCATGTCTATATCTCGCCCAAATGCTGTGGTCGGGAGGTGT
CGCATGATCCGCCACTCAAGAGACAAAAAAAATGAACCCAATCCTCAGAGGTTTGACCGA
ATTGCACACACAAAGGAGACAATGCTCTCTGATGGTTTGAACTCACTCACCTACCAGGTG
CTGGATGTACAGAGATACCCATTGTATACCCAAATCACAGTGGACATCGGGACACCGAGC
TAG

# Drug_Target_3_General_Function:
Involved in transferase activity, transferring glycosyl groups

# Drug_Target_3_General_References:
10580128	Amado M, Almeida R, Schwientek T, Clausen H: Identification and characterization of large galactosyltransferase gene families: galactosyltransferases for all functions. Biochim Biophys Acta. 1999 Dec 6;1473(1):35-53.
1384956	Uejima T, Uemura M, Nozawa S, Narimatsu H: Complementary DNA cloning for galactosyltransferase associated with tumor and determination of antigenic epitopes recognized by specific monoclonal antibodies. Cancer Res. 1992 Nov 15;52(22):6158-63.
1714903	Lopez LC, Youakim A, Evans SC, Shur BD: Evidence for a molecular distinction between Golgi and cell surface forms of beta 1,4-galactosyltransferase. J Biol Chem. 1991 Aug 25;266(24):15984-91.
1903938	Mengle-Gaw L, McCoy-Haman MF, Tiemeier DC: Genomic structure and expression of human beta-1,4-galactosyltransferase. Biochem Biophys Res Commun. 1991 May 15;176(3):1269-76.
2120039	Aoki D, Appert HE, Johnson D, Wong SS, Fukuda MN: Analysis of the substrate binding sites of human galactosyltransferase by protein engineering. EMBO J. 1990 Oct;9(10):3171-8.
2124683	Watzele G, Berger EG: Near identity of HeLa cell galactosyltransferase with the human placental enzyme. Nucleic Acids Res. 1990 Dec 11;18(23):7174.
3091013	Appert HE, Rutherford TJ, Tarr GE, Thomford NR, McCorquodale DJ: Isolation of galactosyltransferase from human milk and the determination of its N-terminal amino acid sequence. Biochem Biophys Res Commun. 1986 Jul 16;138(1):224-9.
3094506	Appert HE, Rutherford TJ, Tarr GE, Wiest JS, Thomford NR, McCorquodale DJ: Isolation of a cDNA coding for human galactosyltransferase. Biochem Biophys Res Commun. 1986 Aug 29;139(1):163-8.
3144273	Masri KA, Appert HE, Fukuda MN: Identification of the full-length coding sequence for human galactosyltransferase (beta-N-acetylglucosaminide: beta 1,4-galactosyltransferase). Biochem Biophys Res Commun. 1988 Dec 15;157(2):657-63.
7540104	Chatterjee SK, Mukerjee S, Tripathi PK: Analysis of the sequences of human beta-1,4-galactosyltransferase cDNA clones. Int J Biochem Cell Biol. 1995 Mar;27(3):329-36.
7579794	Kudo T, Narimatsu H: The beta 1,4-galactosyltransferase gene is post-transcriptionally regulated during differentiation of mouse F9 teratocarcinoma cells. Glycobiology. 1995 Jun;5(4):397-403.
7744867	Yamaguchi N, Fukuda MN: Golgi retention mechanism of beta-1,4-galactosyltransferase. Membrane-spanning domain-dependent homodimerization and association with alpha- and beta-tubulins. J Biol Chem. 1995 May 19;270(20):12170-6.

# Drug_Target_3_HGNC_ID:
HGNC:924

# Drug_Target_3_HPRD_ID:
00659

# Drug_Target_3_ID:
287

# Drug_Target_3_Locus:
9p13

# Drug_Target_3_Molecular_Weight:
43921

# Drug_Target_3_Name:
Beta-1,4-galactosyltransferase 1

# Drug_Target_3_Number_of_Residues:
398

# Drug_Target_3_PDB_ID:
1FR8

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF02709	Galactosyl_T_2

# Drug_Target_3_Protein_Sequence:
>Beta-1,4-galactosyltransferase 1
MRLREPLLSGSAAMPGASLQRACRLLVAVCALHLGVTLVYYLAGRDLSRLPQLVGVSTPL
QGGSNSAAAIGQSSGELRTGGARPPPPLGASSQPRPGGDSSPVVDSGPGPASNLTSVPVP
HTTALSLPACPEESPLLVGPMLIEFNMPVDLELVAKQNPNVKMGGRYAPRDCVSPHKVAI
IIPFRNRQEHLKYWLYYLHPVLQRQQLDYGIYVINQAGDTIFNRAKLLNVGFQEALKDYD
YTCFVFSDVDLIPMNDHNAYRCFSQPRHISVAMDKFGFSLPYVQYFGGVSALSKQQFLTI
NGFPNNYWGWGGEDDDIFNRLVFRGMSISRPNAVVGRCRMIRHSRDKKNEPNPQRFDRIA
HTKETMLSDGLNSLTYQVLDVQRYPLYTQITVDIGTPS

# Drug_Target_3_Reaction:
UDP-galactose + D-glucose = UDP + lactose

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
The cell surface form functions as a recognition molecule during a variety of cell to cell and cell to matrix interactions, as those occurring during development and egg fertilization, by binding to specific oligosaccharide ligands on opposing cells or in the extracellular matrix

# Drug_Target_3_SwissProt_ID:
P15291

# Drug_Target_3_SwissProt_Name:
B4GT1_HUMAN

# Drug_Target_3_Synonyms:
Beta-1,4-GalTase 1
Beta4Gal-T1
EC 2.4.1.-
EC 2.4.1.22
EC 2.4.1.90
N-acetyllactosamine synthase
UDP-Gal:beta-GlcNAc beta-1,4- galactosyltransferase 1
UDP-galactose:beta-N-acetylglucosamine beta- 1,4-galactosyltransferase 1
b4Gal-T1

# Drug_Target_3_Theoretical_pI:
8.77

# Drug_Target_3_Transmembrane_Regions:
25-44

#END_DRUGCARD DB03013
